|
Name |
ergosterol-3-O-β-D-glucopyranoside
|
| Molecular Formula | C34H54O6 | |
| IUPAC Name* |
2-[[17-(5,6-dimethylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
|
| SMILES |
CC(C)C(C)C=CC(C)C1CCC2C3=CC=C4CC(OC5OC(CO)C(O)C(O)C5O)CCC4(C)C3CCC21C
|
|
| InChI |
InChI=1S/C34H54O6/c1-19(2)20(3)7-8-21(4)25-11-12-26-24-10-9-22-17-23(13-15-33(22,5)27(24)14-16-34(25,26)6)39-32-31(38)30(37)29(36)28(18-35)40-32/h7-10,19-21,23,25-32,35-38H,11-18H2,1-6H3/b8-7+/t20-,21+,23-,25+,26?,27?,28?,29?,30?,31?,32?,33-,34+/m0/s1
|
|
| InChIKey |
MKZPNGBJJJZJMI-USHFEQKUSA-N
|
|
| Synonyms |
NA
|
|
| CAS | NA | |
| PubChem CID | NA | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 558.8 | ALogp: | 5.2 |
| HBD: | 4 | HBA: | 6 |
| Rotatable Bonds: | 7 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 99.4 | Aromatic Rings: | 5 |
| Heavy Atoms: | 40 | QED Weighted: | 0.31 |
| Caco-2 Permeability: | -4.797 | MDCK Permeability: | 0.00005120 |
| Pgp-inhibitor: | 0.908 | Pgp-substrate: | 0.036 |
| Human Intestinal Absorption (HIA): | 0.167 | 20% Bioavailability (F20%): | 0.007 |
| 30% Bioavailability (F30%): | 0.273 |
| Blood-Brain-Barrier Penetration (BBB): | 0.223 | Plasma Protein Binding (PPB): | 99.63% |
| Volume Distribution (VD): | 1.925 | Fu: | 2.03% |
| CYP1A2-inhibitor: | 0.002 | CYP1A2-substrate: | 0.134 |
| CYP2C19-inhibitor: | 0.005 | CYP2C19-substrate: | 0.948 |
| CYP2C9-inhibitor: | 0.016 | CYP2C9-substrate: | 0.081 |
| CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.156 |
| CYP3A4-inhibitor: | 0.088 | CYP3A4-substrate: | 0.844 |
| Clearance (CL): | 1.128 | Half-life (T1/2): | 0.044 |
| hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.019 |
| Drug-inuced Liver Injury (DILI): | 0.016 | AMES Toxicity: | 0.114 |
| Rat Oral Acute Toxicity: | 0.557 | Maximum Recommended Daily Dose: | 0.436 |
| Skin Sensitization: | 0.034 | Carcinogencity: | 0.063 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
| Respiratory Toxicity: | 0.918 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC005707 | ![]() |
0.667 | D0G8OC | ![]() |
0.407 | ||
| ENC001092 | ![]() |
0.667 | D0G5CF | ![]() |
0.391 | ||
| ENC004738 | ![]() |
0.667 | D06JPB | ![]() |
0.377 | ||
| ENC001889 | ![]() |
0.652 | D04RYU | ![]() |
0.348 | ||
| ENC005258 | ![]() |
0.638 | D0Y7LD | ![]() |
0.331 | ||
| ENC005238 | ![]() |
0.595 | D0M2QH | ![]() |
0.329 | ||
| ENC001769 | ![]() |
0.559 | D0S0NK | ![]() |
0.325 | ||
| ENC002892 | ![]() |
0.540 | D0N1TP | ![]() |
0.324 | ||
| ENC005270 | ![]() |
0.536 | D07ORO | ![]() |
0.322 | ||
| ENC001984 | ![]() |
0.516 | D01QUS | ![]() |
0.313 | ||